Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine vs Namuscla in Myotonia
NCT05639257Phase 3Unknown
- Start
- Dec 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lamotrigine in non-dystrophic myotonia (NDM) (2 arms). Primary endpoint: Change in Myotonia Behavior Scale at 8 weeks. Status: unknown.
02
Drugs
lamotrigine
03
Conditions
non-dystrophic myotonia (NDM)
Beyond the preview
Go deeper on NCT05639257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639257.